The estrogenic activity of synthetic progestins used in oral contraceptives.
BACKGROUND
Oral contraceptives (OC) contain an orally active estrogen in combination with an orally active synthetic progestin derived from 19-nortestosterone. OC have had an enormous positive impact on public health for the past three decades, and in the main, there has been a remarkably low incidence of troublesome side effects. Although estrogens are implicated in an increased incidence of breast and endometrial cancer, epidemiologic studies have not provided convincing evidence to support a direct correlation between OC use and an increase in breast cancer incidence. By contrast, OC do cause a decrease in the incidence of endometrial and ovarian carcinoma. During the past decade, several isolated reports have linked an increased incidence of breast cancer with the use of synthetic progestins. No mechanism for the proliferative potential of progestins has been offered. Therefore, the authors investigated this problem to formulate a hypothesis, based on laboratory data, that might be evaluated in populations at risk.


METHODS
The synthetic progestins (19-nortestosterone derivatives) chosen for the study were norethynodrel, norethindrone, norgestrel (levonorgestrel), and gestodene. These were compared with the actions of medroxyprogesterone acetate (MPA). To determine whether the progestins produced their effects via the ER, the cells were transfected with a chloramphenicol acetyl transferase (CAT) reporter gene containing an estrogen response element only activated by ER.


RESULTS
The 19-nortestosterone derivatives all stimulated the growth of estrogen receptor (ER)-positive but not ER-negative breast cancer cells in culture. Antiestrogens, but not the antiprogestin mifepristone (also known as RU 486), inhibited progestin-stimulated cell proliferation. MPA did not stimulate cell proliferation. All the synthetic progestins that increased replication also activated CAT. Activation was blocked by antiestrogens but not by mifepristone; the synthetic progestin MPA was inactive.


CONCLUSIONS
These studies provided direct evidence that some synthetic progestins exert estrogenic effects through the ER. The results demonstrated that progestins can have a dual effect on estrogen target tissues either to stimulate or differentiate cells. The results suggest that some beneficial estrogen-like effects could be produced by synthetic progestins (e.g., bone preservation), but epidemiologic studies of OC use should focus of the "total estrogen" content to establish whether some formulations place some groups of women at greater risk of having breast cancer.
Jordan
V C
VC
Department of Human Oncology, University of Wisconsin, Madison 53792.
Jeng
M H
MH
Catherino
W H
WH
Parker
C J
CJ
D001943:Breast Neoplasms / Q000139:chemically induced / Q000453:epidemiology*; D003276:Contraceptives, Oral / Q000009:adverse effects* / Q000494:pharmacology; D005260:Female; D006801:Humans; D015994:Incidence; D045167:Progesterone Congeners / Q000009:adverse effects* / Q000494:pharmacology; D011960:Receptors, Estrogen / Q000032:analysis* / Q000187:drug effects; D014407:Tumor Cells, Cultured
D003276:Contraceptives, Oral; D045167:Progesterone Congeners; D011960:Receptors, Estrogen